Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer

Exclusion Criteria

• •Previous treatment for breast cancer (CT, RT, IT, HT)
• •Stages IIIb, IIIc or IV or invasive bilateral breast cancer
• •Previous neoplasias treated with Anthracyclines or Taxanes (Paclitaxel or Docetaxel)
• •Pregnant or breastfeeding females
• •Neurotoxicity Grade 2
• •FEV≤50% or any cardiac disease in which anthracyclines are contraindicated
• •Other severe diseases regarding investigator criteria
• •Any neurological or psychiatric pathology
• •Previous neoplasia different from breast cancer except:
• •1. skin cancer(no melanoma)
• •2. In situ cervix Carcinoma
• •3. Ipsilateral in situ ductal carcinoma
• •4. In situ lobular in situ carcinoma
• •5. Any other carcinoma without evidence disease in last 10 years
• •Treatment chronic with corticoids (except patients starting 6 months before inclusion with low dosages (\* 20 mg methylprednisolone or equivalent)
• •Concomitant treatment with Hormone ovarian replacement therapy
• •Contraindication for corticoids
• •Concomitant treatment with another investigational drugs
• •Included in another clinical trial with any drug in 30 days before inclusion study
• •Concomitant treatment with another anticancer therapy
• •Male patients
• •Hypersensibility to any study drug or components